James G. Stout, PhD, is vicepresident, Process Sciences, at Natrix Separations, Inc., a part of MilliporeSigma, 5295 John Lucas Drive, Burlington, ON L7L 6A8, Canada.

James G. Stout

Most vaccines available today are still manufactured using antiquated, low-yield, and labor-intensive process technologies in capital-intensive facilities. This lack of manufacturing flexibility drives high cost of goods, diminishes affordability for developing countries, and reduces the market incentive to address smaller patient populations. Improved manufacturing technologies can enable more efficient and cost-effective processes. This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.

Pharmaceutical Technology and BioPharm International

Vaccine Development and Manufacturing 2017

	When referring to this article, please cite it as R. Jacquemart et al., “Achieving Intensification and Flexibility in Virus Purification with Next-Generation Chromatography Tools,” 

 Vaccine Development and Manufacturing 2017 eBook (November 2017).

Articles

This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.